Published in Curr Mol Med on November 01, 2008
Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. J Infect Dis (2009) 1.86
Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling. Cardiovasc Res (2010) 1.05
A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. Int J Gen Med (2010) 1.03
Arginase in retinopathy. Prog Retin Eye Res (2013) 0.94
Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation. Exp Biol Med (Maywood) (2009) 0.94
Arginase and arginine dysregulation in asthma. J Allergy (Cairo) (2011) 0.92
Inhaled nitrite reverses hemolysis-induced pulmonary vasoconstriction in newborn lambs without blood participation. Circulation (2011) 0.92
Arginase Inhibition Reverses Endothelial Dysfunction, Pulmonary Hypertension, and Vascular Stiffness in Transgenic Sickle Cell Mice. Anesth Analg (2016) 0.90
A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica (2013) 0.84
Structural and functional studies indicating altered redox properties of hemoglobin E: implications for production of bioactive nitric oxide. J Biol Chem (2011) 0.83
Nitric oxide synthase enzymes in the airways of mice exposed to ovalbumin: NOS2 expression is NOS3 dependent. Mediators Inflamm (2010) 0.81
FoxO4 Promotes Early Inflammatory Response Upon Myocardial Infarction via Endothelial Arg1. Circ Res (2015) 0.80
Vascular dysfunction as a target for adjuvant therapy in cerebral malaria. Mem Inst Oswaldo Cruz (2014) 0.79
Non-congenital heart disease associated pediatric pulmonary arterial hypertension. Prog Pediatr Cardiol (2009) 0.78
Modulation of Asthma Pathogenesis by Nitric Oxide Pathways and Therapeutic Opportunities. Drug Discov Today Dis Mech (2012) 0.78
Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain. J Pain Res (2014) 0.77
Arginase inhibition enhances angiogenesis in endothelial cells exposed to hypoxia. Microvasc Res (2014) 0.76
Asthma management in sickle cell disease. Biomed Res Int (2013) 0.75
Influence of βS-Globin Haplotypes and Hydroxyurea on Arginase I Levels in Sickle Cell Disease. Dis Markers (2016) 0.75
Hematological disorders and pulmonary hypertension. World J Cardiol (2016) 0.75
B-type natriuretic peptide and plasma hemoglobin levels following transfusion of shorter-storage versus longer-storage red blood cells: Results from the TOTAL randomized trial. Am Heart J (2016) 0.75
Evaluation of carotid artery dynamics & correlation with cardiac & hepatic iron in β-thalassaemia patients. Indian J Med Res (2016) 0.75
Asthma in sickle cell disease: implications for treatment. Anemia (2011) 0.75
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
The L-arginine-nitric oxide pathway. N Engl J Med (1993) 14.38
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med (2004) 10.51
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med (2002) 7.59
Pulmonary arterial hypertension. N Engl J Med (2004) 6.69
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA (2005) 6.49
Arginine metabolism: nitric oxide and beyond. Biochem J (1998) 6.44
Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest (2003) 6.30
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation (2006) 5.91
Primary pulmonary hypertension. N Engl J Med (1997) 4.97
Sickle-cell disease. Lancet (2004) 4.76
Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev (2006) 4.46
Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest (2003) 4.08
Pathogenesis and treatment of sickle cell disease. N Engl J Med (1997) 4.04
Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med (1999) 3.61
Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) (2005) 3.33
Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci U S A (1996) 3.29
Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med (2007) 3.28
The beta-thalassemias. N Engl J Med (1999) 3.19
Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol (2006) 3.02
Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med (2003) 2.93
The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation (2004) 2.88
Endothelial dysfunction in pulmonary hypertension. Circulation (2004) 2.82
Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr (2002) 2.70
Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J (1992) 2.68
Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med (2007) 2.68
Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood (2002) 2.60
Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A (2001) 2.48
Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest (2000) 2.47
Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness. Trends Pharmacol Sci (2003) 2.43
A network model to predict the risk of death in sickle cell disease. Blood (2007) 2.39
Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J (2004) 2.37
Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol (2008) 2.32
Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood (2007) 2.31
Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood (2007) 2.30
Prevalence and reversibility of lower airway obstruction in children with sickle cell disease. J Pediatr (2001) 2.23
Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood (2000) 2.10
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA (2006) 2.04
Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med (2004) 2.01
Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol (2006) 1.99
Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation (2003) 1.98
Causes of death in sickle cell disease: an autopsy study. Br J Haematol (2003) 1.96
Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest (1982) 1.93
Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation (2004) 1.90
Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol (1998) 1.89
The hypercoagulable state in thalassemia. Blood (2002) 1.88
Hemolysis-associated priapism in sickle cell disease. Blood (2005) 1.86
Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax (2005) 1.85
Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med (2003) 1.85
Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. Chest (1995) 1.78
Pulmonary hypertension in sickle cell disease. Am J Med (2004) 1.76
Circumstances of death in adult sickle cell disease patients. Am J Hematol (2006) 1.74
Asthma is associated with increased mortality in individuals with sickle cell anemia. Haematologica (2007) 1.74
Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol (2002) 1.73
Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol (2005) 1.69
Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol (2006) 1.68
Cardiac involvement in thalassemia intermedia: a multicenter study. Blood (2001) 1.67
Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica (2008) 1.67
Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest (2004) 1.67
Reperfusion injury pathophysiology in sickle transgenic mice. Blood (2000) 1.65
Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med (1997) 1.65
Intestinal mucosal amino acid catabolism. J Nutr (1998) 1.65
Increased oxidative stress in lambs with increased pulmonary blood flow and pulmonary hypertension: role of NADPH oxidase and endothelial NO synthase. Am J Physiol Lung Cell Mol Physiol (2006) 1.64
Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol (2000) 1.63
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation (2005) 1.62
Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol (2001) 1.61
Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest (2005) 1.58
Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol (2006) 1.57
Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. Am J Physiol Heart Circ Physiol (2005) 1.57
ADMA and oxidative stress. Atheroscler Suppl (2003) 1.56
Asthma and acute chest in sickle-cell disease. Pediatr Pulmonol (2004) 1.53
Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol (2003) 1.53
Nitric oxide: basic science and clinical applications. Anaesthesia (1994) 1.51
Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol (2006) 1.51
Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood (2001) 1.51
Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med (2006) 1.50
Hypercoagulability in sickle cell disease: a curious paradox. Am J Med (2003) 1.47
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol (2005) 1.47
Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol (2002) 1.45
Pulmonary hypertension in sickle cell disease. Am J Cardiol (1994) 1.44
Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J (2005) 1.44
Induction of arginase I and II in bleomycin-induced fibrosis of mouse lung. Am J Physiol Lung Cell Mol Physiol (2003) 1.44
Human type II arginase: sequence analysis and tissue-specific expression. Gene (1997) 1.42
An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol (2003) 1.41
Cardiac status in well-treated patients with thalassemia major. Eur J Haematol (2004) 1.41
Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol (2007) 1.39
Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev (2000) 1.38
Changing patterns of thalassemia worldwide. Ann N Y Acad Sci (2005) 1.37
Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program (2005) 1.36
Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol (2005) 1.36
Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci (2005) 1.35
Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol (2006) 1.35
Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. Am J Hematol (2008) 1.34
Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol (2006) 1.34
Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol (2005) 1.32
Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med (2001) 1.31
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05
Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med (2003) 8.95
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med (2002) 7.59
The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov (2008) 7.58
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA (2005) 6.49
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
Sickle-cell disease. Lancet (2010) 5.64
Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med (2003) 4.98
Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev (2006) 4.46
Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest (2005) 4.14
Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation (2011) 3.81
Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med (2007) 3.29
Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. J Clin Invest (2005) 3.08
Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ Res (2007) 2.91
Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol (2007) 2.76
Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood (2005) 2.76
Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol (2006) 2.75
Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest (2005) 2.75
Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med (2007) 2.68
Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA (2005) 2.47
Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation (2007) 2.46
A network model to predict the risk of death in sickle cell disease. Blood (2007) 2.39
The reaction between nitrite and deoxyhemoglobin. Reassessment of reaction kinetics and stoichiometry. J Biol Chem (2005) 2.34
Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood (2007) 2.31
Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood (2007) 2.30
Catalytic generation of N2O3 by the concerted nitrite reductase and anhydrase activity of hemoglobin. Nat Chem Biol (2007) 2.30
Nitrate and nitrite in biology, nutrition and therapeutics. Nat Chem Biol (2009) 2.29
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Mortality increases after massive exchange transfusion with older stored blood in canines with experimental pneumonia. Blood (2012) 2.22
NO contest: nitrite versus S-nitroso-hemoglobin. Circ Res (2004) 2.21
Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica (2009) 2.20
Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2008) 2.17
Nitrite as regulator of hypoxic signaling in mammalian physiology. Med Res Rev (2009) 2.15
Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. Circulation (2008) 2.14
The relationship between pulmonary emphysema and kidney function in smokers. Chest (2012) 2.13
Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat Med (2004) 2.09
Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood (2005) 2.08
Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood (2004) 2.06
Measurement of circulating nitrite and S-nitrosothiols by reductive chemiluminescence. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 2.06
Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol (2009) 2.05
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA (2006) 2.04
Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest (2003) 2.00
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA (2009) 1.88
Methodologies for the sensitive and specific measurement of S-nitrosothiols, iron-nitrosyls, and nitrite in biological samples. Free Radic Res (2003) 1.81
Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol (2006) 1.79
Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One (2008) 1.75
Storage lesion: role of red blood cell breakdown. Transfusion (2011) 1.74
The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica (2012) 1.72
Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA (2012) 1.72
Human neuroglobin functions as a redox-regulated nitrite reductase. J Biol Chem (2011) 1.70
Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med (2008) 1.69
Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol (2005) 1.69
Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovasc Res (2007) 1.69
Biological activity of nitric oxide in the plasmatic compartment. Proc Natl Acad Sci U S A (2004) 1.68
Washing older blood units before transfusion reduces plasma iron and improves outcomes in experimental canine pneumonia. Blood (2013) 1.66
Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity. Cardiovasc Res (2014) 1.65
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood (2011) 1.64
Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Radic Biol Med (2006) 1.63
A novel molecular signature for elevated tricuspid regurgitation velocity in sickle cell disease. Am J Respir Crit Care Med (2012) 1.63
Nitric oxide scavenging by red blood cells as a function of hematocrit and oxygenation. J Biol Chem (2005) 1.61
Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation. Circulation (2009) 1.58
Inhaled nitric oxide decreases infarction size and improves left ventricular function in a murine model of myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol (2006) 1.57
Concerted nitric oxide formation and release from the simultaneous reactions of nitrite with deoxy- and oxyhemoglobin. J Biol Chem (2007) 1.57
Nitrite therapy after cardiac arrest reduces reactive oxygen species generation, improves cardiac and neurological function, and enhances survival via reversible inhibition of mitochondrial complex I. Circulation (2009) 1.57
Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. Free Radic Biol Med (2011) 1.56
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol (2005) 1.47
Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program (2008) 1.45
Copper dependence of the biotin switch assay: modified assay for measuring cellular and blood nitrosated proteins. Free Radic Biol Med (2008) 1.43
An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol (2003) 1.41
Nitrite regulates hypoxic vasodilation via myoglobin-dependent nitric oxide generation. Circulation (2012) 1.40
Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA (2011) 1.38
The measurement of blood and plasma nitrite by chemiluminescence: pitfalls and solutions. Free Radic Biol Med (2006) 1.38
Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program (2005) 1.36
Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol (2005) 1.36
Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias. Free Radic Biol Med (2006) 1.36
Measurement of nitric oxide levels in the red cell: validation of tri-iodide-based chemiluminescence with acid-sulfanilamide pretreatment. J Biol Chem (2006) 1.36
Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med (2012) 1.35
Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol (2010) 1.35
Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci (2005) 1.35
Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol (2006) 1.35
Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol (2006) 1.34
Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. Am J Hematol (2008) 1.34
Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. Am J Hematol (2008) 1.34